63. Dermatomyositis

  1. Hywel C. Williams DSc, FRCP4,
  2. Michael Bigby MD5,
  3. Andrew Herxheimer MB, FRCP6,
  4. Luigi Naldi MD7,
  5. Berthold Rzany MD, ScM8,
  6. Robert P. Dellavalle MD, PhD, MSPH9,
  7. Yuping Ran10 and
  8. Masutaka Furue11
  1. Ruth Ann Vleugels1,
  2. David F. Fiorentino2 and
  3. Jeffrey P. Callen3

Published Online: 6 JUN 2014

DOI: 10.1002/9781118357606.ch63

Evidence-Based Dermatology, 3

Evidence-Based Dermatology, 3

How to Cite

Vleugels, R. A., Fiorentino, D. F. and Callen, J. P. (2014) Dermatomyositis, in Evidence-Based Dermatology, 3 (eds H. C. Williams, M. Bigby, A. Herxheimer, L. Naldi, B. Rzany, R. P. Dellavalle, Y. Ran and M. Furue), John Wiley & Sons, Ltd, Oxford, UK. doi: 10.1002/9781118357606.ch63

Editor Information

  1. 4

    Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK

  2. 5

    Department of Dermatology, Harvard Medical School, and Beth Israel Deaconess Medical Center, Boston, MA, USA

  3. 6

    UK Cochrane Centre, Oxford, UK

  4. 7

    Centro Studi Gruppo Italiano Studi Epidemiologici in Dermatologia, Department of Dermatology, Ospedali Riuniti, Bergamo, Italy

  5. 8

    RZANY & HUND, Privatpraxis für Dermatologie und Ästhetische Medizin, Berlin, Germany

  6. 9

    Department of Dermatology, University of Colorado Denver, Aurora, USA

  7. 10

    Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, P. R. China

  8. 11

    Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, Japan

Author Information

  1. 1

    Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

  2. 2

    Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA

  3. 3

    Division of Dermatology, University of Louisville School of Medicine, Louisville, KY, USA

Publication History

  1. Published Online: 6 JUN 2014
  2. Published Print: 1 AUG 2014

ISBN Information

Print ISBN: 9781118357675

Online ISBN: 9781118357606

SEARCH

Keywords:

  • corticosteroid-sparing agents;
  • dermatomyositis;
  • malignancy

Summary

This chapter talks about dermatomyositis, which is one of the idiopathic inflammatory myopathies. It discusses the incidence, prevalence, etiology, prognosis and diagnostic tests for dermatomyositis. The skin disease is often symptomatic, often associated with prominent pruritus, and is cosmetically displeasing. The goal of therapy is therefore to relieve the symptoms and improve the patient's quality of life. The chapter focuses on the risk of malignancy in the patient with dermatomyositis or amyopathic dermatomyositis. In addition, it focuses on clinical or laboratory findings that are associated with a greater risk of malignancy, and effectiveness of dermatomyositis treatments. Observations from individual case reports and small case series suggest that, for skin disease, hydroxychloroquine, methotrexate, and mycophenolate mofetil are effective corticosteroid-sparing agents. A retrospective series suggests that patients with dermatomyositis may have an increased risk of drug eruption to hydroxychloroquine.